Apatinib with chemo for advanced osteosarcoma
Treatments studied
Part of Cancer clinical trials.
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have osteosarcoma that has continued to grow or come back after at least two standard treatments.
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are physically able to do most daily activities (ECOG score 0 or 1) and expected to live at least 3 months.
- You have not been treated with apatinib or irinotecan (or similar drugs) before.
- Any side effects from prior treatments (except hair loss) have resolved or are mild.
- Your major organs (like kidneys, liver, and bone marrow) are working well enough, as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding trilaciclib to standard chemotherapy before surgery for patients with newly diagnosed, high-grade osteosarcoma. Trilaciclib may help protect healthy cells during chemo treatment.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial tests a combination of two drugs, losartan and sunitinib, in people with osteosarcoma that has come back or spread after prior treatment. The study aims to see if this combination is safe and effective.
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
This trial tests a new drug, HS-20093, combined with other treatments for people with advanced bone or soft tissue sarcoma. The goal is to see if these combinations can shrink tumors or slow their growth.
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.